Multiplex assay separates domain-specific ADA responses using a PEGylated Cas9 model
Academic source · Bioanalysis
Source published: · Event / reporting date: 2026-11-03
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What the paper reports
A Bioanalysis paper describes development and prevalidation of a Luminex xMAP assay for simultaneous domain-specific anti-drug antibody detection. Using PEGylated Cas9 as a model, the authors report adjustable bead ratios and on-demand coupling to accommodate different minimum required dilutions. The original abstract supports assay feasibility, rather than universal validation across multidomain therapeutics or demonstrated clinical benefit.
Why this paper is included
Analysis: Multiplexing may reduce sample use and assay burden for complex modalities, subject to domain-specific sensitivity, interference, and clinical suitability assessment.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Edited by the Biotech Assistant content team and reviewed by an authorized publisher. Editorial standards and corrections